Peptide Straight Talk · Issue #3 · November 2026 · Educational only, not medical advice
A surprise in a Belgian lab
In 2012, chemists at an anti-doping laboratory at Ghent University in Belgium ran a product called TB-500 through a mass spectrometer. That's an instrument that weighs molecules with extreme precision, and it has no idea what the label says. The name pointed toward thymosin beta-4 (Tβ4), a natural repair protein made of 43 amino acids, the small building blocks the body strings together like beads.
The instrument had other ideas. "It was immediately evident that TB-500 did not contain the endogenous Tβ4," the team wrote. ("Endogenous" just means the body's own version.) What they found was much smaller: a 7-piece fragment from the middle of the protein, with a tiny chemical cap on one end.[1]
That same year, over in Hong Kong, a racing laboratory reported the same 7-piece peptide as the "key ingredient" of a veterinary TB-500 product used in racehorses.[2]
Fourteen years later, TB-500 is everywhere, especially as one half of the popular "Wolverine" stack. So this issue comes in two parts. Part 1 sorts out the science: which molecule is which, and what's actually been tested. Part 2 tells the story of the Wolverine stack, which runs from a calf thymus and a Zagreb lab to the racetrack and a comic-book hero. And one puzzle tags along the whole way: the label.
Part 1: The science
What people are saying
TB-500's story starts at the racetrack, not the gym. The U.S. Food and Drug Administration (FDA) says a veterinary preparation of TB-500 "appeared in 2011 and was marketed to boost performance in equine and greyhound sports."[3] From there, it found its way to people. A study of 13 online doping forums, cited by FDA, found that TB-500 "emerged as a topic of discussion" after 2010 and became one of the two most-mentioned substances in its category.[3]
These days, most people meet TB-500 through recovery stories:
Lifters and athletes talk about nagging tendon, muscle and joint injuries that finally seemed to settle down.
The Wolverine pairing. TB-500 often gets paired with BPC-157 (short for body protection compound 157), the peptide we covered in Issue #2. Fans call the combo "Wolverine," after the comic-book character who heals from almost anything. Part 2 of this issue tells that story.
People on the mend after surgery or a long layoff describe feeling looser and bouncing back faster.
Some of those stories may reflect real change. Some may be the body healing on its own, given time. And some may be the placebo effect, when people feel better because they expect to. Stories alone can't tell those apart, which is exactly what controlled studies are for.
TB-500 has been in the news, too. In July 2026, an FDA advisory committee reviewed it. In Brazil, the health regulator Anvisa (the National Health Surveillance Agency) published a resolution on October 6, 2026. It ordered the seizure of a blend listed by name as "BPC157 & TB500," along with other unregistered products offered online and presented as intended for research purposes. The order also banned their storage, sale, distribution, manufacture, advertising, transport and use. Anvisa announced another enforcement action on October 14 covering unregistered products sold online, including products labeled TB-500 and BPC-157. Both actions target specific products sold under those names, not the substances in general. Neither one says what the products actually contain, and neither mentions thymosin beta-4.[4][56] More on both under "TB-500's regulatory status."
Prefer to watch? Choose either video: the highlights only, or the full article.
Highlights only (about 10 min):
Full article video (about 50 min):
What people hope it does
FDA's review lists what TB-500 is marketed online to do, and it's a long list.[3] Among the claims:
healing tendons, muscles, ligaments and bones
faster wound healing and less scar tissue
calmer inflammation
better flexibility, endurance and heart health
even hair growth and relief for dry eyes
That's a lot to ask of one molecule. As we'll see, a few of these hopes have been tested in people, but with full-length thymosin beta-4, not TB-500. A few more have been tested in animals. Most haven't been tested for TB-500 itself at all.
Why people believe it
The curiosity didn't come out of nowhere. There are real reasons behind it.
Tβ4 is one of the body's own repair proteins. It shows up in nearly every cell and in body fluids like blood, saliva, tears and wound fluid.[3] Platelets, the blood cells that start clotting, release it at the site of an injury, where it helps kick off the repair process.[5] Its day job is managing actin, the protein cells use to change shape and move.[6]
Striking animal results. In 1999, researchers at the National Institutes of Health (NIH) reported that Tβ4 sped up skin-wound healing in rats.[7] Two later papers in the journal Nature reported that it helped mouse hearts recover after a blocked artery and woke up repair cells in the heart's outer layer.[8][9]
A small piece that seemed to do a big job. In 2003, NIH researchers found that a 7-amino-acid stretch of Tβ4, written in one-letter code as LKKTETQ (positions 17 to 23), matched the whole protein in lab tests of blood-vessel cell movement.[10] A lab-made copy of that stretch also helped skin wounds close in aged mice.[11] That little stretch is the scientific seed of TB-500.
The name carries the reputation. Many sellers describe TB-500 as "synthetic thymosin beta-4." And that's where things get confusing.
One name, two molecules
This is the heart of the issue. People often use "TB-500" and "thymosin beta-4" as if they mean the same thing. By the official definitions, they don't.
Full-length thymosin beta-4 is the natural protein: 43 amino acids, with a molecular weight of about 4,963. Drug companies have tested versions of it in people.
TB-500, according to FDA's May 2026 review, "is understood today to be a seven amino acid synthetic fragment of thymosin beta-4 (β4) from amino acids 17 to 23 and an acetyl group at the N-terminal leucine amino acid." In plain English: positions 17 to 23 of the protein, plus a small chemical cap (an acetyl group) on the front end. Chemists write it as Ac-LKKTETQ. Its molecular weight is about 889, roughly one-sixth the size of the full protein.[3]
So why won't the confusion go away? A few reasons.
The name isn't official. FDA notes that "TB-500 is a common name and not a United States Adopted Name (USAN)," and that it has "encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name." An active moiety is the part of a molecule that does the work. Translation: different molecules have been sold under the same name.[3]
Sellers use the terms interchangeably. FDA put it plainly: "Several websites state that TB-500 is a synthetic version of thymosin beta-4 and often use the terms interchangeably. However, as noted previously, thymosin beta-4 and TB-500 are not the same substance."[3] So the popular line "TB-500 is synthetic thymosin beta-4" doesn't match how FDA defines TB-500.
ID numbers get mixed up. Chemicals get registry numbers from CAS (Chemical Abstracts Service), and the full protein and the fragment each have their own. FDA noticed several suppliers' websites using the fragment's number for a different salt form of it.[3] And in our own check of blend listings (more below), nearly half used the full protein's number for "TB-500."
Science and the market speak different languages. Clinical trials say "thymosin beta 4" or use drug code names. Products say "TB-500." So when people go looking for the human research, they find studies of full-length Tβ4 and assume it covers TB-500. A 2026 scoping review of 80 studies found that 70 tested Tβ4 itself, while just one directly tested TB-500.[12]
Rulebooks group them together. The World Anti-Doping Agency (WADA) bans "Thymosin-ß4 and its derivatives e.g. TB-500" in a single line.[13] That makes sense for anti-doping, but it's easy to read as "same thing."
Even researchers blur it. A 2026 rat study described its test product as "synthetic thymosin beta-4 (TB-500)."[15] A 2026 sports-medicine review lumped the two together under one label, "thymosin beta-4 or TB-500,"[16] and another 2026 review called TB-500 "thymosin beta-500," a name FDA doesn't use.[17] If the journals mix it up, nobody else should feel bad about it.
Why this matters: evidence for one molecule doesn't automatically carry over to the other. FDA makes that point even about TB-500's uncapped cousin. Adding an acetyl cap changes a peptide's charge and shape, so FDA says results for uncapped LKKTETQ "cannot be directly extrapolated" to TB-500.[3]
What the science shows, molecule by molecule
We label each finding by the kind of evidence behind it:
Human: studies in people.
Animal: studies in rats, mice, horses or other animals.
In vitro: studies of cells in a dish (Latin for "in glass").
Full-length thymosin beta-4
In vitro and animal. This is a deep body of work. In lab dishes, Tβ4 got skin cells and blood-vessel cells moving and sprouting.[7][10] In animals, it sped up skin-wound healing in normal, diabetic and aged rodents[7][11] and supported heart repair in mice.[8][9] In the 2026 scoping review, most of the 80 included studies were lab and animal work on Tβ4.[12]
Human: eye drops. A U.S. company developed Tβ4 eye drops under the code name RGN-259.
Then came bigger trials. One with 317 people hasn't posted results.[22] Two more, with about 600 and 700 people, missed their main goals, according to the company's own announcements in 2017 and 2021. Each did report improvement on some secondary measures, such as eye discomfort or a gritty feeling.[59][60] Both have also posted average results to the ClinicalTrials.gov registry, the most recent on August 28, 2026, without a statistical analysis.[23][24]
For neurotrophic keratopathy, a rare condition where damaged nerves keep the clear front of the eye (the cornea) from healing, one trial found complete healing in 6 of 10 people on the drops versus 1 of 8 on placebo. That fell just short of the usual bar for statistical significance, and the trial was stopped early for a business decision.[25][26] A 2025 Cochrane review, an independent summary of the evidence, rated this finding as low certainty.[27] A follow-up trial is still listed as recruiting, though its estimated completion date has come and gone and the record hasn't been updated since December 2025.[28]
Human: skin gel. A gel version, code name RGN-137, was tested on hard-to-heal wounds.
In a trial for venous ulcers (leg sores caused by poor blood flow in the veins) that randomized 73 people (the registry lists 72), safety was comparable to placebo, and the authors wrote that one strength "may have the potential to accelerate wound healing."[29][30] A 72-person trial in pressure ulcers (bedsores) was also completed.[31] A review by researchers involved in the program reported that, among patients whose wounds did heal, healing came almost a month faster.[5]
Human: given into a vein. Tβ4 has also been tested as an IV (intravenous) infusion.
In China, a lab-made (recombinant) version was well tolerated in 84 healthy volunteers across two early studies.[36] In a 96-person trial in people with a serious type of heart attack called STEMI (ST-elevation myocardial infarction), the area of heart muscle damaged by the heart attack did not differ significantly between treatment and placebo overall. A subgroup treated within eight hours after the artery-opening procedure had a smaller damaged area at 90 days; that finding needs confirmation.[37] A 189-person follow-up trial is listed as not yet recruiting.[38]
Controlled human evidence remains missing for tendon and muscle repair. In other words, the very injuries most people ask about. The 2026 scoping review found no human trials of Tβ4 or TB-500 in those tissues.[12]
The TB-500 fragment (Ac-LKKTETQ)
In vitro. Results are mixed, and the details matter.
Then there's the one lab study of capped TB-500 that both FDA and the 2026 review point to. In it, TB-500 didn't speed the closing of scratch "wounds" in a layer of connective-tissue cells. One of its breakdown products, a shorter 5-piece fragment, did produce what FDA called "a small, but significant wound closure."[40][3][12]
Animal. Here the cupboard is nearly bare.
Human. No published human trials found. FDA's review says that "no articles were found in which TB-500 was administered to humans,"[3] and the 2026 scoping review also came up empty on human studies of TB-500.[12] One wrinkle since then: a small dental case report described three people who were given a product labeled TB-500 as part of a mix. More on that in the next section.
Labeled "TB-500," exact form not stated
One study doesn't fit neatly in either box, and it happens to be the only controlled study of the Wolverine pair (more in Part 2). In a 2026 Turkish study of rats with surgically repaired Achilles tendons, the group given a product labeled TB-500 was the only group with a significant gain in tendon strength, and it also had better tissue scores. BPC-157 alone also had higher strength numbers than the untreated group, but the difference wasn't statistically significant. This small study did not demonstrate an added benefit from combining the two.[15]
Two cautions. First, the paper describes its test product as "synthetic thymosin beta-4" and doesn't report its sequence or molecular weight, so we can't tell whether it tested the 7-piece fragment or the full protein. (Yes, the label puzzle follows us right into the journals.) Second, it was small: eight rats per group, with four tendons from each group used for strength testing and the other four for tissue analysis, over four weeks. The authors themselves call it "exploratory."[15]
One newer paper belongs in this box too, and this one involves people. A 2026 dental case report described three patients left with numbness from nerve injuries after dental surgery. Each received a combination of three peptides—including BPC-157 and a substance described as TB-500—plus a steroid and a local anesthetic containing epinephrine. The authors reported improved sensation in all three during follow-up. The authors call the cases "hypothesis-generating." With no comparison group and several agents together, there's no way to tell which part helped. It's also possible the nerves would have recovered on their own, which the authors note is common after some of these injuries. And, true to form, the paper doesn't say which molecule its TB-500 was.[63]
The evidence at a glance
Results in one column don't automatically apply to another.
TB-500's regulatory status
FDA
FDA has not approved TB-500 for any use, and it hasn't approved any of the thymosin beta-4 products from the trials above either. FDA also found no approved TB-500 products in Canada, Australia, the United Kingdom or several European countries, and none authorized by the European Medicines Agency.[3]
The compounding story
Compounding is when a pharmacy mixes a custom medicine. Under a part of federal law called Section 503A, pharmacies can only use certain ingredients, and one route is a list FDA keeps, often called the "bulks list."
FDA previously placed "Thymosin beta-4, fragment (LKKTETQ)" in Category 2, its group of compounding ingredients that "may present significant safety risks," pointing to a possible risk of immune reactions.[14]
Since then: FDA's page lists "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" among substances whose nominations were withdrawn (checked October 31, 2026).[14] That withdrawal, on its own, isn't permission to compound it.
July 23, 2026: FDA brought TB-500 to its Pharmacy Compounding Advisory Committee (PCAC), a panel of outside experts.[41] FDA staff recommended not adding it to the bulks list, citing the absence of human data, missing safety studies and a possible risk of immunogenicity (the immune system reacting to the substance).[3] The committee voted separately on the two forms, free base and acetate. According to legal-industry reports, each vote came out 8 yes, 6 no, with 1 abstaining, in favor of adding it.[42][43] As of October 31, 2026, FDA's meeting page listed briefing documents, presentations and video of the meeting, but no minutes, transcript or official vote tally.[62]
Brazil
Brazil's health regulator, Anvisa, ordered the seizure of a blend sold as "BPC157 & TB500" (published October 6). Anvisa announced another enforcement action on October 14 covering unregistered products sold online, including products labeled TB-500 and BPC-157. Both actions target specific products, not the substances in general.[4][56]
WADA
WADA's 2026 Prohibited List bans "Thymosin-ß4 and its derivatives e.g. TB-500" at all times for tested athletes, under growth factors (section S2.3).[13] The ban is actually older than the name on the list. The 2010 list already banned growth factors that affect muscle, tendon or ligament repair, without naming Tβ4,[57] and Tβ4 and TB-500 were named outright starting with the 2018 list.[58] Anti-doping scientists have been building tests for TB-500's breakdown products for years; FDA notes that WADA approved a research project on them in 2013.[3]
What we're still waiting to learn
Does full-length Tβ4 help the injuries people care about? The human trials tested eye drops, skin gel and IV infusions for eye, skin and heart conditions, not tendon or muscle injuries.[12]
Does stacking add anything? The one controlled study of the combination was in rats. This small study did not demonstrate an added benefit from combining the two.[15] In people, the only reports are uncontrolled: four patients in a clinic chart review, and three dental patients who got the pair as part of a multi-agent treatment.[55][63] Part 2 has the full story.
Is new research on the way? So far, new work is still mostly about the full protein. We searched PubMed and the ClinicalTrials.gov registry for records added from August through October 28, 2026. This window uses database-entry dates: the rat tendon paper was published July 23 but entered PubMed August 2.[15] Apart from the rat tendon study above, every new lab and animal study we found was on full-length Tβ4, and none tested the TB-500 fragment itself. The other newly identified papers that mention TB-500 by name were reviews, commentary and the dental case report above. None was a controlled study. The only new trial results posted in that window came from a full-length Tβ4 eye-drop trial.
Part 2: The Wolverine stack, a history
If TB-500 has a famous best friend, it's BPC-157. Online, the pair goes by a superhero name: the "Wolverine stack." (In peptide talk, a stack just means two or more products used together.)
So how did a thymus protein, a stomach peptide from Zagreb, the racetrack and a comic-book hero all end up in the same vial? It's a stranger trip than you'd guess, so we'll take it chapter by chapter. Some of it is solidly on the record. Some of it is the kind of story that gets repeated in forums until it starts to feel like fact. We'll mark which is which as we go:
Documented: backed by a paper, a government record, a court ruling or the original source itself.
Lore: widely repeated, but we couldn't find a primary source. Lore isn't necessarily wrong. It's just unproven, the stuff everybody has heard and nobody can source.
Chapter 1: Two molecules with very different childhoods
TB-500's family tree starts with a calf thymus
Our story opens in the mid-1960s, with scientists hunting for the hormones of the thymus, a small gland behind the breastbone that helps train immune cells. They partially purified a substance from calf thymus and called it "thymosin."[46] It turned out not to be one thing at all, but a mix of many proteins.
In 1981, researchers published the full sequence of one of them: a 43-amino-acid protein named thymosin beta-4. At the time, it was studied as a possible thymus hormone.[47] (Documented.)
Then the story took a turn. Tβ4 isn't really a thymus thing at all. It showed up in nearly every cell in the body, where its everyday job is managing actin, the protein cells use to move and change shape.[3][6] Named after one gland, employed by the whole body. One of the original thymosin researchers founded a company in 1982 that later focused on Tβ4 and took it into the eye, skin and heart trials described earlier in this issue.[48] (Documented.)
You already know the next steps from Part 1: the 1999 NIH wound-healing study in rats, and the 2003 discovery that a 7-piece stretch, LKKTETQ, did some of the protein's work in lab tests.[7][10] That stretch is the scientific seed of TB-500. The name "TB-500" came later, and it didn't come from a journal.
BPC-157 is the Zagreb half
We told BPC-157's origin story in Issue #2, so here's the short version. It's a lab-made, 15-amino-acid peptide based on part of a larger protein that a research group in Zagreb (then Yugoslavia, now Croatia) reported finding in human gastric juice. Yes, stomach juice. The group's original patent claims priority from 1989, and the group described the 15-piece fragment in papers by 1993. A Croatian drugmaker later tested it for inflammatory bowel disease. Most of its research since then has been in animals, and much of it comes from the original group. (Documented; see Issue #2 for sources.)
So by the early 2000s, both halves of the future Wolverine stack existed, in separate labs on separate continents. We found no sign of anyone pairing them up yet. As far as the record shows, they hadn't even been introduced.
Chapter 2: The racetrack years (2003–2012)
TB-500's first public career wasn't in people. It was in animal sports. According to FDA, TB-500 "appears to have first been synthesized from thymosin β4 in 2003," and a veterinary preparation "appeared in 2011 and was marketed to boost performance in equine and greyhound sports."[3] (Documented.)
Racing labs noticed. In 2012, labs in Hong Kong and Ghent, Belgium, both identified the capped 7-piece fragment in products sold as TB-500, as described at the top of this issue.[1][2]
In the U.S., the Racing Medication & Testing Consortium, a horse-racing industry group, put out a bulletin warning that the capped fragment was "being marketed for use in the horse" and was "sometimes referred to generically as TB-500." It described lab testing at the University of California, Davis, of products labeled TB500. The results were a surprise. Many contained no thymosin beta-4 or anything derived from it. Most contained no proteins, peptides or amino acids at all. One sample did contain the capped fragment. The group recommended that racing regulators treat it as a substance in their most serious category.[49] (Documented.)
Let that sit for a second: most of the tested products named after a peptide had no peptide in them. Hold on to that finding, because "the name on the bottle didn't match what was inside" turns out to be the running theme of this whole story.
Lore check: you'll sometimes see stories about famous racehorses caught with TB-500, or about trainers "discovering" it. We didn't find a documented U.S. racing case to cite, so we're leaving those stories in the barn.
Chapter 3: Crossing over to people (2010–2016)
From the barn, TB-500 found its way into the gym. A study of 13 online doping forums, cited by FDA, found that TB-500 "emerged as a topic of discussion" after 2010 and became one of the two most-mentioned substances in its category.[3] A German anti-doping lab found thymosin beta-4 itself among black-market products it analyzed between 2010 and 2013.[44] (Documented.)
Then thymosin beta-4 landed in sports headlines, and from an unexpected place: Australian football.
In 2012, the Essendon Football Club of the Australian Football League (AFL) ran a supplements program for its players. Australia's anti-doping authority later brought cases alleging that players had been injected with thymosin beta-4. In March 2015, the AFL's own tribunal cleared the players. The World Anti-Doping Agency (WADA) appealed. Then, on January 11, 2016, the Court of Arbitration for Sport ruled that 34 current and former players had committed anti-doping violations and handed them two-year bans, which kept those still playing out of the 2016 season.[50][51] (Documented.)
Two details matter for our story. First, the case was about thymosin beta-4, not TB-500 specifically. Second, the AFL tribunal and the sports court looked at the same case and reached opposite conclusions. That tells you how hard it can be to pin down what was actually injected.
Anti-doping rules caught up in stages. WADA's 2010 list already banned growth factors that affect muscle, tendon or ligament repair, without naming Tβ4.[57] Starting with the 2018 list, WADA named "Thymosin-β4 and its derivatives, e.g. TB-500" outright.[58] BPC-157 joined the list in 2022, under unapproved substances (covered in Issue #2).
Chapter 4: Enter Wolverine (2016 onward)
Wolverine is the Marvel Comics hero with the metal claws. He made his first full appearance in The Incredible Hulk #181, cover-dated November 1974.[52] He became best known for his "healing factor," the power to bounce back from almost any injury. For a recovery peptide, that's about as good as branding gets.
The first documented link we found: on May 16, 2016, a popular fitness podcaster and biohacking author published an online guide to BPC-157 with "Healing The Body Like Wolverine" in the title.[53] (Documented.) Now notice who's missing from that headline: TB-500. The article was about BPC-157 alone. Its comment section, still online, does include readers talking about pairing it with TB-500.
Who named the stack? (Lore.) The earliest Wolverine reference we found is a 2016 article about BPC-157 alone.[53] We could not establish who first applied the name to the pair. So the honest answer is lore. Good nicknames tend to have plenty of proud parents and very little paperwork.
When did it take off? Some sites say readers paired the two "within days" of that 2016 article, or give a year when the stack hit Reddit or clinic marketing. We couldn't verify those dates, so file them under lore too. What we can say is that by the 2020s, "Wolverine" had become shorthand for BPC-157 plus TB-500 across forums, videos and product listings.
The name isn't fixed. In 2024, the same author published a "Recover Like Wolverine" stack with five peptides: BPC-157, TB-500 and three others.[54] (Documented.) So "Wolverine" on a label can mean two peptides or more. It's a nickname, not a formula. Even superheroes pick up a few sidekicks.
Chapter 5: Why the pairing made sense to people
The usual pitch goes something like this. In animal studies, BPC-157 is linked to blood-vessel growth and gut protection. TB-500 is linked to actin and cell movement. So one supposedly fixes the "plumbing" while the other moves the "repair crews" into place, and together they cover more ground.
It's a tidy story, and it's easy to see why it caught on. Each half has a body of lab and animal research behind it. For TB-500, though, most of that research is on the full Tβ4 protein or the uncapped fragment, not TB-500 itself (see Part 1).
But the "they complement each other" idea is a hypothesis. It's a reasonable guess, built from studies of each molecule on its own. Nobody has shown it in people. A good story and a tested result aren't the same thing, and so far this one is still a good story.
A few practical things helped the pairing spread, too. Both peptides were widely sold online as "research" products, and one-vial blends made the combination easy to buy. Regulators have noticed those blends by name (more in Chapter 8).
Chapter 6: What happens when someone actually tests the pair
Here's the part of the story that rarely makes it into the forums.
Animal. The only controlled study of the combination we found is the 2026 Turkish rat study from Part 1. Thirty-two rats with repaired Achilles tendons were split into four groups of eight: no treatment, BPC-157, a product labeled TB-500, or both. Within each group, four tendons went to strength testing and four to tissue analysis. The verdict? This small study did not demonstrate an added benefit from combining the two. (In the authors' words, the combination "did not confer additional benefits compared to either agent alone.") The authors suggested the two might work through overlapping pathways, and said that idea still needs testing.[15]
Human. Here the data get thin fast, and none of it is controlled. We found two reports. The first is a look back through patient charts at one U.S. clinic, covering 2019 to 2020. Of 16 people with knee pain who were reached by phone afterward, 12 had received a BPC-157 injection into the knee and 4 had received BPC-157 plus thymosin beta-4 (the paper doesn't say which form). Three of those 4 reported significant improvement.[55] The second is the 2026 dental case report from Part 1. Three people with nerve injuries after dental surgery each received a combination of three peptides—including BPC-157 and a substance described as TB-500—plus a steroid and a local anesthetic containing epinephrine. The authors reported improved sensation in all three during follow-up.[63] These are starting points, not answers. Neither report had a comparison group, the dental cases combined several agents, and seven people is a very small number. Reports like these can't tell us whether the pair works, or whether it does anything beyond BPC-157 alone.
Bottom line: as of October 28, 2026, no controlled human trial of the Wolverine stack has been published. The big question, whether the combination helps people heal better than either peptide alone or than time and rehab, is not yet addressed.
Chapter 7: The label puzzle, round two
Remember the racetrack bulletin, where products named TB500 often didn't contain what the name implied? That theme never really left. It just changed outfits.
Someone on our team recently came across a Wolverine stack whose product name says TB-500 while its detailed product listing names thymosin beta-4. The name points to one molecule, and the fine print points to another. We haven't seen a lab test of that product, so what's actually in the vial is unverified.
That made us curious how common it is, so we checked. On October 6, 2026, we looked at 24 public online listings for BPC-157 + TB-500 blends found through web search, and we rechecked the same listings on October 26. By then, 21 were still online and readable. Here's what their detailed specs (molecular weight, chemical formula, amino-acid sequence or CAS registry number) described for the "TB-500" half:
8 of 21 described full-length thymosin beta-4, not the 7-piece fragment.
6 of 21 described the fragment.
4 of 21 mixed details from different molecules on the same page.
3 of 21 gave no molecular details at all.
Nearly half the listings (10 of 21) used the full protein's CAS number somewhere.
A few honest caveats. This was a web-search sample, not a survey of the whole market. Listings are descriptions, not lab results. We didn't buy or test anything, and we didn't independently check any certificates that sellers posted.
Published lab testing tells a similar story: the name hasn't always meant the same thing. Besides the 2012 findings and the racing bulletin, a French racing lab reported in 2023 that the contents of products sold as TB500 and TB1000 were "not systematically consistent" with earlier descriptions.[45] We didn't find any published independent lab test of a Wolverine blend.
The takeaway on labels: a blend's label doesn't reliably tell you which molecule its "TB-500" half is meant to be, and the research behind the two molecules isn't the same.
Chapter 8: From nickname to government paperwork (2023–2026)
In a decade, the Wolverine pair went from a blog headline to official documents on two continents. (All documented.)
FDA previously placed BPC-157 and the thymosin beta-4 fragment in Category 2, its group of nominated compounding ingredients that may present significant safety risks. Its current page lists both among substances whose nominations were withdrawn.[14]
July 2026: FDA's outside advisory committee reviewed both. By reported counts, it voted 8–6–1 in favor of adding each to the compounding list, against FDA staff's recommendation.[42]
What the Wolverine stack still doesn't have is a controlled human trial. We hope researchers write that chapter next.
The Wolverine stack at a glance
When | What happened | Status |
|---|---|---|
1966 | "Thymosin" partially purified from calf thymus | Documented |
1981 | Thymosin beta-4's 43-amino-acid sequence published | Documented |
1989–1993 | Zagreb group files BPC patent claims (priority 1989) and describes the 15-piece BPC 157 fragment | Documented (Issue #2) |
1999–2003 | NIH: Tβ4 speeds wound healing in rats; the LKKTETQ stretch is active in lab tests | Documented |
2003 | TB-500 "appears to have first been synthesized" (per FDA) | Documented |
2010 | WADA's list bans growth factors in general, covering Tβ4 without naming it | Documented |
2011 | Veterinary TB-500 marketed for horse and greyhound racing (per FDA) | Documented |
2012 | Hong Kong and Belgian labs identify the capped fragment in TB-500 products | Documented |
2016 | Essendon players banned in a thymosin beta-4 case | Documented |
2016 | "Healing The Body Like Wolverine" headline on a BPC-157 guide | Documented |
2016–2020s | The two-peptide "Wolverine stack" name catches on; who first named it could not be established | Lore |
2018 | WADA names "Thymosin-β4 and its derivatives, e.g. TB-500" | Documented |
2021 | Small clinic chart review includes 4 people given BPC-157 plus Tβ4 | Documented (weak evidence) |
2022 | BPC-157 added to WADA's list | Documented |
Before nomination withdrawal | FDA listed both substances in Category 2.[14] | Documented |
2026 | Rat study: did not demonstrate an added benefit from combining the two | Documented (animal) |
2026 | Dental case report: 3 people given the pair within a multi-agent treatment | Documented (weak evidence) |
2026 | FDA advisory committee reviews both; Brazil names the blend | Documented |
The Wolverine stack in five sentences
The two halves grew up apart: TB-500 descends from a thymus protein first sequenced in 1981, and BPC-157 from a Zagreb gastric-juice project.
TB-500 broke out at the racetrack around 2011, and the anti-doping world has been chasing it ever since.
The earliest Wolverine reference we found is a 2016 article about BPC-157 alone.[53] We could not establish who first applied the name to the pair.
The "they complement each other" logic is a hypothesis. The one controlled study of the pair was a small rat study that did not demonstrate an added benefit from combining the two, and we found two small uncontrolled reports involving seven people given BPC-157 with substances described as thymosin beta-4 or TB-500; three also received other agents.
What's in a Wolverine vial has been a question since the beginning, and a label alone doesn't settle which molecule is inside.
Where that leaves us
Is the science against TB-500? No. For the fragment, the central question, whether it helps people heal, is not yet addressed, because we found no published human trials of the fragment. For full-length thymosin beta-4, the human results are mixed and specific to eye, skin and heart conditions.
The Wolverine stack is a great story: a thymus protein, a stomach peptide, a racetrack and a superhero. The science behind the pair just hasn't caught up with its fame yet. There's no controlled human trial of the combination, and one small rat study did not demonstrate an added benefit from combining the two.
From a Belgian lab bench in 2012 to a Wolverine listing in 2026, the name TB-500 has meant different things to different people. Knowing which molecule is which is the first step to reading the evidence clearly. Meanwhile, we'll keep watching for the human trials that could fill in the gaps.
Coming up in Issue #4
Next month: PT-141. Unlike most peptides we cover, this one has an FDA-approved version. Bremelanotide, sold as Vyleesi, was approved in 2019 for acquired, generalized hypoactive sexual desire disorder (a specific diagnosis of persistently low sexual desire) in premenopausal women.[61] We'll look at how it grew out of research on a sunless-tanning peptide (yes, really), what the trials showed, and how the approved drug compares with what's sold online as "PT-141."
Peptide Straight Talk is educational only. Nothing here is medical advice or a recommendation to use any product.
Peptide Straight Talk. Clear evidence, plain language, no hype.
Sources
All 63 sources for this issue are listed on a separate page: See the full source list →
